<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836508</url>
  </required_header>
  <id_info>
    <org_study_id>1909</org_study_id>
    <nct_id>NCT03836508</nct_id>
  </id_info>
  <brief_title>Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis</brief_title>
  <official_title>Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sisli Hamidiye Etfal Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sisli Hamidiye Etfal Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded, randomized controlled trial evaluating medium cut-off dialyzer compared to
      high flux dialyzer in ironic hemodialysis patients over a 6 months period with 3 months
      crossovers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pre and post-dialysis of Interleukin (IL) 17-A</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of IL-17A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of IL-10</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of Interferon (IFN) gama</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of IFN gama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis necrosis factor (TNF) alpha</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of TNF alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of IL-4</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of IL-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of Urea</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of Urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of creatinine</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of beta2 microglobulin</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of beta2 microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of free light chain kappa</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of free light chain kappa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of free light chain lambda</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of free light chain lambda</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of myoglobulin</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of myoglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis of fibroblast growth factor (FGF) 23</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis of FGF 23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis IL-18 levels</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis IL-18 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis monocyte chemoattractant protein (MCP)-1 levels</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis MCP-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis NACHT, LRR and PYD domains-containing protein3 (NLRP3) levels</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis NLRP3 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre and post-dialysis regulated on activation, normal T cell expressed and secreted (RANTES)</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of pre and post-dialysis RANTES</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Kidney Failure</condition>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Dialysis Related Complication</condition>
  <arm_group>
    <arm_group_label>Medium cut-off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medium cut-off</intervention_name>
    <description>All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.
Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min</description>
    <arm_group_label>High-flux</arm_group_label>
    <arm_group_label>Medium cut-off</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-Flux</intervention_name>
    <description>All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.
Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min</description>
    <arm_group_label>High-flux</arm_group_label>
    <arm_group_label>Medium cut-off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are older than 18 years and younger than 65 years

          -  patient with end-stage renal disease, hemodialysis more than 6 months

          -  patients under hemodialysis with high-flux dialyzer more than 3 months

          -  patients willing to participate after given fair and clear information about study

        Exclusion Criteria:

          -  patients living with Hepatitis B or C,

          -  patients with malignancy

          -  patients under immunosuppressive treatment

          -  patients with autoimmune diseases such as systemic lupus erythematosus, etc.

          -  patients with active infections

          -  patients planned to have a kidney transplantation in 6 months

          -  patients having vascular access problems

          -  patients planned to transfer to another center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mustafa Sevinc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sisli Hamidiye Etfal Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sisli Hamidiye Etfal Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sisli Hamidiye Etfal Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Nuri Baris Hasbal</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03836508/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

